Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.54 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.54 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.54 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792326 | 0.85 | HPGD (0.54) | HPGDLMNA | |
| SCHEMBL660115 | 0.85 | HPGD (0.62) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL6289160 | 0.85 | HPGD (0.62) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL6289159 | 0.85 | HPGD (0.62) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL11731507 | 0.83 | KMT2A (0.65) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL5574769 | 0.83 | LMNA (0.66) | HPGDKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2191045 | 0.83 | KDM4E (0.65) | NPC1RAB9ASMN1; SMN2LMNAPLAAT3 | |
| SCHEMBL4584283 | 0.82 | NPC1 (0.64) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL16681873 | 0.82 | NPC1 (0.74) | HPGDPOLBKMT2ANPC1RAB9A | |
| SCHEMBL17335855 | 0.82 | HPGD (0.73) | HPGDPOLBKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944635-B2 | Deuterated pyrazino[2,1-a]isoquinoline compounds and methods of treatment using the same | CONCERT PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160060263-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9206179-B2 | Methods of use comprising deuterated pyrazino[2,1-a]isoquinolines | CONCERT PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9199986-B2 | Deuterated pyrazino[2,1-a]isoquinolines for the treatment of diseases and/or conditions | CONCERT PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8889687-B2 | Deuterated pyrazinoisoquinoline compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2014-04-17 | — | — | US | disclosed |
| US-8563554-B2 | Deuterated pyrazinoisoquinoline compounds | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130029997-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120149709-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885POLB 2573/4885KMT2A 761/4885 |
| US-20130029997-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885POLB 2573/4885KMT2A 761/4885 |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | ACHE, ABCC5, ABCC2 | HPGD 887/4885POLB 3431/4885KMT2A 1887/4885 |
| US-20160060263-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | P2RX5, ABCC5, ABCC2 | HPGD 718/4885POLB 3001/4885KMT2A 1972/4885 |
| US-20120149709-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | P2RX5, ABCC5, ABCC2 | HPGD 718/4885POLB 3001/4885KMT2A 1972/4885 |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | HPGD 918/4885POLB 2573/4885KMT2A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.